RenovoRx, Inc. (RNXT)
Market: NASD |
Currency: USD
Address: 4546 El Camino Real
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
📈 RenovoRx, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$5.50
-
Upside/Downside from Analyst Target:
298.55%
-
Broker Call:
8
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for RenovoRx, Inc.
| Date | Reported EPS |
|---|
| 2026-05-13 (estimated upcoming) | - |
| 2026-03-30 (estimated upcoming) | - |
| 2025-11-12 (estimated upcoming) | - |
| 2025-11-11 (estimated upcoming) | - |
| 2025-08-13 (estimated upcoming) | - |
| 2025-05-15 | - |
| 2025-04-01 | - |
| 2025-03-31 | -0.13 |
| 2024-11-13 | -0.1 |
| 2024-08-13 | -0.1 |
| 2024-05-10 | -0.07 |
| 2024-04-01 | -0.31 |
| 2023-11-13 | -0.13 |
| 2023-08-16 | -0.31 |
| 2023-05-12 | -0.36 |
| 2023-03-02 | -0.23 |
| 2022-11-14 | -0.24 |
| 2022-08-12 | -0.29 |
| 2022-05-13 | -0.33 |
| 2022-03-30 | -0.12 |
| 2021-11-15 | -0.27 |
| 2021-08-27 | - |
📰 Related News & Research
No related articles found for "renovorx inc".
